Online citations, reference lists, and bibliographies.
← Back to Search

The Therapeutic Potential Of Nanoscale Sphingolipid Technologies.

Jody L Hankins, Ushma A. Doshi, Jeremy K. Haakenson, Megan M Young, Brian M Barth, M. Kester
Published 2013 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Nanotechnologies, while small in size, widen the scope of drug delivery options for compounds with problematic pharmacokinetics, such as bioactive sphingolipids. We describe the development of historical sphingolipid nanotechnologies, such as nanoliposomes, and project future uses for a broad repertoire of nanoscale sphingolipid therapy formulations. In particular, we describe sphingo-nanotherapies for treatment of cancer, inflammatory disease, and cardiovascular disease. We conclude with a discussion of the challenges associated with regulatory approval, scale-up, and development of these nanotechnology therapies for clinical applications.
This paper references
10.1016/j.pharmthera.2011.08.004
Development of small-molecule inhibitors of sphingosine-1-phosphate signaling.
Yvette Edmonds (2011)
10.1016/j.biomaterials.2011.06.028
Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic® for tumor-targeted delivery of docetaxel.
H. Cho (2011)
10.1182/blood-2010-02-271080
Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia.
X. Liu (2010)
10.1089/scd.2007.0271
Propagation of undifferentiated human embryonic stem cells with nano-liposomal ceramide.
U. Salli (2009)
10.4049/jimmunol.0902926
Ceramide and Ceramide 1-Phosphate Are Negative Regulators of TNF-α Production Induced by Lipopolysaccharide
S. Jozefowski (2010)
10.1023/A:1024409123726
A Phase II Study of Topical Ceramides for Cutaneous Breast Cancer
A. Jatoi (2004)
10.1073/PNAS.64.1.290
Release of trapped marker from liposomes by the action of purified complement components.
J. Haxby (1969)
Encapsula - tion of organic molecules in calcium phosphate nanocomposite particles for intracellular imaging and drug delivery
TT Morgan (2008)
10.1074/jbc.M109.080671
Studies on the Role of Acid Sphingomyelinase and Ceramide in the Regulation of Tumor Necrosis Factor α (TNFα)-converting Enzyme Activity and TNFα Secretion in Macrophages*
K. A. Rozenova (2010)
10.1161/01.RES.87.4.282
Ceramide-Coated Balloon Catheters Limit Neointimal Hyperplasia After Stretch Injury in Carotid Arteries
R. Charles (2000)
10.1002/(SICI)1097-0215(19990412)81:2<268::AID-IJC17>3.0.CO;2-1
GD2‐mediated melanoma cell targeting and cytotoxicity of liposome‐entrapped fenretinide
G. Pagnan (1999)
10.1126/SCIENCE.1070238
Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists
S. Mandala (2002)
10.1038/nature02284
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
M. Matloubian (2004)
10.1074/JBC.M111.276048
WITHDRAWN: Ceramide kinase regulates the production of TNFα via inhibition of TNFα-converting enzyme
Nadia F. Lamour (2011)
10.1021/nl801908y
Organelle-targeted nanocarriers: specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo.
S. Boddapati (2008)
10.1007/s10719-008-9192-y
Use of a novel anti-proliferative compound coated on a biopolymer to mitigate platelet-derived growth factor-induced proliferation in human aortic smooth muscle cells: comparison with sirolimus
Yong-dan Tang (2008)
10.4161/cbt.12.7.15971
Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancer
Y. Jiang (2011)
10.1002/ijc.22886
Paclitaxel and ceramide co‐administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer
H. Devalapally (2007)
10.2174/156727008785133809
C(6)-Ceramide-Coated Catheters Promote Re-Endothelialization of Stretch-Injured Arteries.
S. M. O'Neill (2008)
10.1124/JPET.103.054056
Liposomal Delivery Enhances Short-Chain Ceramide-Induced Apoptosis of Breast Cancer Cells
Tom Stover (2003)
10.4161/cbt.10.11.13438
Inhibition of NADPH oxidase by glucosylceramide confers chemoresistance
Brian M Barth (2010)
10.1074/jbc.M111.264010
Exogenous Ceramide-1-phosphate Reduces Lipopolysaccharide (LPS)-mediated Cytokine Expression*
Jody L Hankins (2011)
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.
Y. Matsumura (1986)
10.1016/S0022-2836(65)80093-6
Diffusion of univalent ions across the lamellae of swollen phospholipids.
A. Bangham (1965)
10.1016/J.COPH.2006.09.008
Sphingosine-1-phosphate signaling in the cardiovascular system.
S. Peters (2007)
10.1158/1078-0432.CCR-07-4881
Combining Nanoliposomal Ceramide with Sorafenib Synergistically Inhibits Melanoma and Breast Cancer Cell Survival to Decrease Tumor Development
Melissa A. Tran (2008)
10.1158/0008-5472.CAN-06-1648
Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer.
Lilian E van Vlerken (2007)
10.1002/JPS.21182
Cytotoxicity and apoptosis enhancement in brain tumor cells upon coadministration of paclitaxel and ceramide in nanoemulsion formulations.
Ankita Desai (2008)
10.1016/0014-5793(90)81016-H
Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes
A. Klibanov (1990)
10.1074/JBC.C000587200
The Lipids C2- and C16-Ceramide Form Large Stable Channels
L. Siskind (2000)
10.1158/0008-5472.CAN-06-2117
Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy.
F. Pastorino (2006)
10.1038/nnano.2007.223
Immunological properties of engineered nanomaterials
M. Dobrovolskaia (2007)
10.1074/jbc.M111.310169
Ceramide Kinase Regulates the Production of Tumor Necrosis Factor α (TNFα) via Inhibition of TNFα-converting Enzyme*
Nadia F. Lamour (2011)
10.1006/FAAT.1995.1056
Toxicity of the protein kinase C inhibitor safingol administered alone and in combination with chemotherapeutic agents.
L. Kedderis (1995)
10.1002/JSS.400110415
Modulation of cell surface iron transferrin receptors by cellular density and state of activation.
J. Larrick (1979)
10.1189/jlb.0108076
Inhibition of corneal inflammation by liposomal delivery of short‐chain, C‐6 ceramide
Y. Sun (2008)
10.1111/J.1432-1033.1972.TB19710.X
Fate of protein-containing liposomes injected into rats. An approach to the treatment of storage diseases.
G. Gregoriadis (1972)
10.1074/JBC.C200176200
The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors*
V. Brinkmann (2002)
10.1016/j.jconrel.2011.11.002
In vivo efficacy of a novel liposomal formulation of safingol in the treatment of acute myeloid leukemia.
Kuan-Boone Tan (2012)
10.1021/nl802098g
Calcium phosphate nanocomposite particles for in vitro imaging and encapsulated chemotherapeutic drug delivery to cancer cells.
M. Kester (2008)
Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
F. Pastorino (2003)
10.1073/PNAS.87.15.5744
Lipid composition is important for highly efficient target binding and retention of immunoliposomes.
K. Maruyama (1990)
10.1021/nn102324e
Nanoparticulate alternatives for drug delivery.
James H. Adair (2010)
Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation
A. Rahman (2007)
10.1158/1078-0432.CCR-10-2323
A Phase I Clinical Trial of Safingol in Combination with Cisplatin in Advanced Solid Tumors
M. Dickson (2011)
10.1002/jcp.21101
Ceramide inhibits LPS‐induced production of IL‐5, IL‐10, and IL‐13 from mast cells
N. Chiba (2007)
10.1124/dmd.107.019679
Rapid Distribution of Liposomal Short-Chain Ceramide in Vitro and in Vivo
Banu S Zolnik (2008)
Complement-mediated lysis of liposomes produced by the reactive lysis procedure.
P. Lachmann (1970)
10.1038/nrd3324
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
V. Brinkmann (2010)
10.1016/J.IJPHARM.2005.10.002
Effect of lipid-containing, positively charged nanoemulsions on skin hydration, elasticity and erythema--an in vivo study.
E. Yılmaz (2006)
10.4161/cbt.13.1.18871
Increased apoptosis in cancer cells in vitro and in vivo by ceramides in transferrin-modified liposomes
Alexander Koshkaryev (2012)
10.2174/187152011797655177
Ceramide-based therapeutics for the treatment of cancer.
Brian M Barth (2011)
10.1016/0005-2736(89)90078-3
Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues.
T. Allen (1989)
10.1016/j.biomaterials.2011.10.064
Polyethylene glycol-conjugated hyaluronic acid-ceramide self-assembled nanoparticles for targeted delivery of doxorubicin.
H. Cho (2012)
10.1016/S0005-2736(03)00108-1
Intracellular delivery of ceramide lipids via liposomes enhances apoptosis in vitro.
J. A. Shabbits (2003)
High ceramide content liposomes with in vivo antitumor activity.
J. A. Shabbits (2003)
10.1016/J.BIOMATERIALS.2007.09.037
Thermoresponsive and biodegradable linear-dendritic nanoparticles for targeted and sustained release of a pro-apoptotic drug.
Thomas C. Stover (2008)
10.1021/nl8019888
Encapsulation of organic molecules in calcium phosphate nanocomposite particles for intracellular imaging and drug delivery.
Thomas T. Morgan (2008)
10.1038/sj.bjp.0703516
Sphingosine‐1‐phosphate reduces rat renal and mesenteric blood flow in vivo in a pertussis toxin‐sensitive manner
A. Bischoff (2000)
10.1016/0014-5793(87)80506-9
Large unilamellar liposomes with low uptake into the reticuloendothelial system
T. Allen (1987)
10.1002/JSSCB.1981.380160305
Monoclonal antibody covalently coupled to liposomes: specific targeting to cells.
J. Barbet (1981)
10.1136/gut.2010.216671
Nanoliposomal ceramide prevents in vivo growth of hepatocellular carcinoma
H. S. Tagaram (2010)
10.1158/1078-0432.CCR-04-1770
Systemic Delivery of Liposomal Short-Chain Ceramide Limits Solid Tumor Growth in Murine Models of Breast Adenocarcinoma
Thomas C. Stover (2005)
Calcium phosphate nanocomposite
M Kester (2008)
10.1016/j.ejphar.2008.02.089
Sphingolipid signalling in the cardiovascular system: good, bad or both?
A. Alewijnse (2008)
10.1016/j.colsurfb.2009.09.001
Biodegradable polymeric nanoparticles based drug delivery systems.
A. Kumari (2010)
10.1007/s11095-011-0457-y
Targeted Delivery to Neuroblastoma of Novel siRNA-anti-GD2-liposomes Prepared by Dual Asymmetric Centrifugation and Sterol-Based Post-Insertion Method
Joanna E. Adrian (2011)
10.1158/1078-0432.CCR-07-4973
Modulation of Drug Resistance in Ovarian Adenocarcinoma by Enhancing Intracellular Ceramide Using Tamoxifen-Loaded Biodegradable Polymeric Nanoparticles
H. Devalapally (2008)
10.1096/fj.10-163709
Enriching lipid nanovesicles with short‐chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors
M. Lummel (2011)
10.1021/nn901297q
Bioconjugation of calcium phosphosilicate composite nanoparticles for selective targeting of human breast and pancreatic cancers in vivo.
Brian M Barth (2010)
10.1002/JPS.2600840420
Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system.
D. Bazile (1995)
10.3109/09687688.2010.521200
Receptor-targeted nanocarriers for therapeutic delivery to cancer
B. Yu (2010)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar